A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

Next Previous
Trial Profile

A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs AAV RPGR Gene Therapy NightstaRx (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man
  • Acronyms XIRIUS
  • Sponsors Nightstar Therapeutics; NightstaRx

    • Most Recent Events

    • 03 Apr 2018 According to a Nightstar Therapeutics media release, the company expects the initial data on safety and tolerability from the dose escalation cohorts of this trial to be available towards the end of 2018; this data will determine the dose for study in an expansion cohort anticipated to include up to 30 patients.
    • 22 Mar 2017 New trial record
    • 19 Mar 2017 According to a NightstaRx media release, the company has commenced enrolling and dosing subjects in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top